DK1272633T3 - Præparater og fremgangsmåder til dendritisk celle-baseret immunterapi - Google Patents
Præparater og fremgangsmåder til dendritisk celle-baseret immunterapiInfo
- Publication number
- DK1272633T3 DK1272633T3 DK01920913.9T DK01920913T DK1272633T3 DK 1272633 T3 DK1272633 T3 DK 1272633T3 DK 01920913 T DK01920913 T DK 01920913T DK 1272633 T3 DK1272633 T3 DK 1272633T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- immunostimulatory
- preparations
- dendritic cell
- based immunotherapy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 5
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19350400P | 2000-03-30 | 2000-03-30 | |
| PCT/US2001/010515 WO2001074855A2 (en) | 2000-03-30 | 2001-03-30 | Compositions and methods for dendritic cell-based immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1272633T3 true DK1272633T3 (da) | 2011-05-23 |
Family
ID=22713907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01920913.9T DK1272633T3 (da) | 2000-03-30 | 2001-03-30 | Præparater og fremgangsmåder til dendritisk celle-baseret immunterapi |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7060279B2 (https=) |
| EP (1) | EP1272633B1 (https=) |
| JP (1) | JP5110674B2 (https=) |
| AT (1) | ATE507295T1 (https=) |
| AU (2) | AU4791901A (https=) |
| CA (1) | CA2403964C (https=) |
| CY (1) | CY1111718T1 (https=) |
| DE (1) | DE60144516D1 (https=) |
| DK (1) | DK1272633T3 (https=) |
| ES (1) | ES2362715T3 (https=) |
| NZ (1) | NZ522066A (https=) |
| PT (1) | PT1272633E (https=) |
| WO (1) | WO2001074855A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7198920B1 (en) | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
| US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
| US7413869B2 (en) * | 2002-04-05 | 2008-08-19 | Dendreon Corporation | Method for determining potency of antigenic presenting cell based vaccines |
| WO2003087338A2 (en) * | 2002-04-11 | 2003-10-23 | Amgen, Inc. | Her-2 receptor tyrosine kinase molecules and uses thereof |
| US7597894B2 (en) | 2003-03-05 | 2009-10-06 | Dendreon Corporation | Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease |
| WO2007147165A2 (en) * | 2006-06-16 | 2007-12-21 | Bresagen, Inc. | Human cancer stem cell culture compositions comprising erbb2 variants and methods of use thereof |
| US7972602B2 (en) | 2006-08-11 | 2011-07-05 | Dendreon Corporation | Promiscuous HER-2/Neu CD4 T cell epitopes |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US8309096B2 (en) | 2007-01-15 | 2012-11-13 | Glaxosmithkline Biologicals S.A. | Fusion protein |
| AR064863A1 (es) * | 2007-01-15 | 2009-04-29 | Glaxosmithkline Biolog Sa | Proteina de fusion |
| JP2010532656A (ja) * | 2007-01-15 | 2010-10-14 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 癌退縮抗原ｎｙ−ｅｓｏ−１およびｌａｇｅ−１を含む融合タンパク質 |
| WO2008118369A2 (en) * | 2007-03-22 | 2008-10-02 | Dendreon Corporation | Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity |
| JP6426001B2 (ja) * | 2011-11-17 | 2018-11-21 | グリア エスピー ゼット．オー．オー． | 神経膠腫を治療するための組成物および方法 |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| WO2017096247A1 (en) | 2015-12-04 | 2017-06-08 | Mayo Foundation For Medical Education And Research | Methods and vaccines for inducing immune responses to multiple different mhc molecules |
| CA3184940A1 (en) | 2020-07-07 | 2022-01-13 | Jennifer Donglan WU | Mic antibodies and binding agents and methods of using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2048981B (en) * | 1979-05-23 | 1982-11-17 | Coal Ind | Equipment for laying a layer of elongate material adjacent to an exposed rock or mineral surface in an underground mine |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| CA2158281A1 (en) * | 1993-03-15 | 1994-09-29 | Jay A. Berzofsky | Peptide coated dendritic cells as immunogens |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US5586538A (en) * | 1995-11-13 | 1996-12-24 | Caterpillar Inc. | Method of correcting engine maps based on engine temperature |
| US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| WO1998046769A1 (en) * | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| US6194152B1 (en) * | 1997-08-20 | 2001-02-27 | Dendreon Corporation | Prostate tumor polynucleotide compositions and methods of detection thereof |
| JP2002532514A (ja) * | 1998-12-14 | 2002-10-02 | デンドレオン コーポレイション | 主要組織適合性複合体クラスｉ拘束抗原提示の増強のための、組成物および方法 |
| HUP0105303A2 (en) * | 1999-01-29 | 2002-05-29 | Corixa Corp | Her-2/neu fusion proteins |
| DE60014076T2 (de) * | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
| US6406681B1 (en) * | 2000-08-21 | 2002-06-18 | Aeropharm Technology, Inc. | Method of treating a systemic disease |
-
2001
- 2001-03-30 WO PCT/US2001/010515 patent/WO2001074855A2/en not_active Ceased
- 2001-03-30 AT AT01920913T patent/ATE507295T1/de active
- 2001-03-30 DK DK01920913.9T patent/DK1272633T3/da active
- 2001-03-30 US US09/821,883 patent/US7060279B2/en not_active Expired - Fee Related
- 2001-03-30 JP JP2001572544A patent/JP5110674B2/ja not_active Expired - Fee Related
- 2001-03-30 EP EP01920913A patent/EP1272633B1/en not_active Expired - Lifetime
- 2001-03-30 AU AU4791901A patent/AU4791901A/xx active Pending
- 2001-03-30 PT PT01920913T patent/PT1272633E/pt unknown
- 2001-03-30 CA CA2403964A patent/CA2403964C/en not_active Expired - Fee Related
- 2001-03-30 AU AU2001247919A patent/AU2001247919B2/en not_active Ceased
- 2001-03-30 DE DE60144516T patent/DE60144516D1/de not_active Expired - Lifetime
- 2001-03-30 ES ES01920913T patent/ES2362715T3/es not_active Expired - Lifetime
- 2001-03-30 NZ NZ522066A patent/NZ522066A/en not_active IP Right Cessation
-
2005
- 2005-06-03 US US11/144,912 patent/US7659117B2/en not_active Expired - Fee Related
-
2011
- 2011-07-20 CY CY20111100718T patent/CY1111718T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1272633B1 (en) | 2011-04-27 |
| JP2003529608A (ja) | 2003-10-07 |
| US7659117B2 (en) | 2010-02-09 |
| ATE507295T1 (de) | 2011-05-15 |
| JP5110674B2 (ja) | 2012-12-26 |
| CY1111718T1 (el) | 2015-10-07 |
| DE60144516D1 (de) | 2011-06-09 |
| ES2362715T3 (es) | 2011-07-12 |
| AU2001247919B2 (en) | 2006-02-09 |
| AU4791901A (en) | 2001-10-15 |
| CA2403964A1 (en) | 2001-10-11 |
| CA2403964C (en) | 2013-04-30 |
| WO2001074855A2 (en) | 2001-10-11 |
| NZ522066A (en) | 2004-08-27 |
| PT1272633E (pt) | 2011-06-27 |
| EP1272633A2 (en) | 2003-01-08 |
| US7060279B2 (en) | 2006-06-13 |
| WO2001074855A3 (en) | 2002-03-07 |
| US20020061310A1 (en) | 2002-05-23 |
| US20050232932A1 (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111718T1 (el) | Συνθεσεις και μεθοδοι για ανοσοθεραπεια βασιζομενη σε δενδριτικα κυτταρα | |
| DK0870022T3 (da) | Immunstimulerende sammensætning og fremgangsmåde | |
| DK1002110T3 (da) | Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner | |
| WO1999006544A8 (en) | Membrane-bound cytokine compositions and methods of modulating an immune response using same | |
| MXPA02010670A (es) | Nuevas moleculas co-estimuladoras de celula dendritica. | |
| WO2003068941A3 (en) | Modulation of immune response by non-peptide binding stress response polypeptides | |
| DE60331224D1 (de) | Subtilisin-carlsberg-proteine mit verminderter immunogenität | |
| ATE551069T1 (de) | Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung | |
| WO2005000884A8 (en) | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli | |
| GB0113798D0 (en) | Antigens and vectors for vaccination | |
| AU2363301A (en) | Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes | |
| GB0401239D0 (en) | Adjuvant compositions | |
| WO2001094949A3 (en) | Soluble cd1 compositions and uses thereof | |
| NZ500151A (en) | A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence | |
| DE60130634D1 (de) | Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden | |
| PT996636E (pt) | Antigenio ha-1 | |
| DK1578772T3 (da) | Cytokiner og cytokinreceptorer med reduceret immunogenicitet | |
| WO2002051237A3 (en) | Helicobacter proteins, nucleic acids and uses thereof | |
| WO2004020592A3 (en) | Retroductal salivary gland genetic vaccination | |
| EP1561817A3 (en) | Modified CEA and uses thereof |